Cervical cancer technology company, TruScreen Limited (NZAX: TRU), is pleased to announce the appointment of Professor Ron Jones as an independent director on the TruScreen Board, effective from Tuesday, 17 October, 2017.
Prof. Jones is a retired obstetrician and gynaecologist and was a former clinical professor at the University of Auckland, as well as serving on the Auckland University of Technology ethics committee. He is a widely published international authority of lower genital tract pre-cancer and cancer. For over 30 years he has served on a range of national and international committees addressing the natural history, prevention and management of these cancers. He is a past president of the International Society for the Study of Vulvovaginal Disease and chair of the Scientific Committee of the International Federation of Cervical Pathology and Colposcopy.
Prof. Jones has been involved with the TruScreen technology since the very beginning and was the Principal Investigator for a 1998 study at National Women’s Hospital in Auckland, one of the key clinics used to gather early data for what was then the Cervical PolarProbe (and has now evolved into TruScreen). The data generated in that study was used to “inform” or “train” the tissue differentiating algorithm that was first placed into the TruScreen device.
Chairman of TruScreen, Mr Robert Hunter, commented: “We are privileged to have Prof. Jones join the TruScreen Board. He is arguably one of New Zealand’s most highly qualified gynaecologists, has been involved in a number of highly regarded international clinical studies on new clinical technologies and has experience working with, and advising governments, at the highest level.
“TruScreen is now entering the commercialisation phase and presentations to health ministries and key opinion leaders are a critical component of our business plan. Prof. Jones’ international profile and his extensive experience and expertise will be a significant advantage for our company as we look to expand and build on our global footprint.”
Prof. Jones is ordinarily resident in New Zealand and has been appointed by the current TruScreen directors, as permitted under TruScreen’s constitution. He will hold office until TruScreen’s 2018 Annual Meeting at which time he will offer himself for election by shareholders. Following Prof. Jones’ appointment the TruScreen Board will comprise of three independent directors and one nonexecutive director.
– ENDS –
For more information visit www.truscreen.com or contact:
Martin Dillon TruScreen Chief Executive Officer Email: firstname.lastname@example.org
Media Liaison Jackie Ellis Email: email@example.com Phone: +64 27 246 2505
TruScreen’s real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection.